^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Excerpt:
NSCLC subjects with EGFR mutation and/or ALK rearrangement and/or ROS-1 positive, should have received appropriate targeted therapy and are refractory to targeted therapy prior to enrolling this trial.
Trial ID:
Source:
Title:
Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis
Published date:
08/08/2023
Excerpt:
Neoadjuvant sintilimab plus chemotherapy showed superior efficacy in localized EGFR-mutant NSCLC.
Trial ID:
Source:
Title:
Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression - Free and Overall Survival
Published date:
08/22/2021
Excerpt:
...receive docetaxel (75mg/m2, day 1) plus sintilimab (200mg, day 3) every 3 weeks for 4-6 cycles...Median DOR was 6.46 months (95% 1.28, NA). Median TTR (Time to Response) was 3.89 months (95% 1.61, 4.99)….the first study of a PD-1 inhibitor plus chemotherapy in advanced Chinese NSCLC patients who had failed first-line standard therapy. The encouraging efficacy and tolerable safety profile suggest a potential role of this combination in second-line setting.
Secondary therapy:
docetaxel
